Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
14.95
Dollar change
-0.41
Percentage change
-2.67
%
IndexRUT P/E- EPS (ttm)-3.34 Insider Own22.76% Shs Outstand29.56M Perf Week-12.06%
Market Cap533.86M Forward P/E- EPS next Y-3.63 Insider Trans0.00% Shs Float27.58M Perf Month-19.23%
Income-107.69M PEG- EPS next Q-0.84 Inst Own79.46% Short Float40.63% Perf Quarter2.54%
Sales0.00M P/S- EPS this Y-17.55% Inst Trans-10.93% Short Ratio11.47 Perf Half Y7.63%
Book/sh5.59 P/B2.67 EPS next Y-10.26% ROA-58.19% Short Interest11.20M Perf Year-51.32%
Cash/sh5.58 P/C2.68 EPS next 5Y- ROE-65.21% 52W Range8.12 - 43.69 Perf YTD2.96%
Dividend Est.- P/FCF- EPS past 5Y- ROI-51.55% 52W High-65.78% Beta-0.54
Dividend TTM- Quick Ratio12.49 Sales past 5Y0.00% Gross Margin- 52W Low84.00% ATR (14)1.31
Dividend Ex-Date- Current Ratio12.49 EPS Y/Y TTM-37.07% Oper. Margin0.00% RSI (14)43.26 Volatility6.31% 8.82%
Employees83 Debt/Eq0.06 Sales Y/Y TTM- Profit Margin- Recom1.14 Target Price48.86
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q-2.14% Payout- Rel Volume0.83 Prev Close15.36
Sales Surprise- EPS Surprise2.24% Sales Q/Q- EarningsOct 30 AMC Avg Volume976.78K Price14.95
SMA20-8.34% SMA50-10.58% SMA200-10.19% Trades Volume808,391 Change-2.67%
Date Action Analyst Rating Change Price Target Change
Feb-06-24Initiated Truist Buy $55
Jul-27-23Initiated Scotiabank Sector Outperform $41
Jun-26-23Downgrade Jefferies Buy → Hold
May-12-23Initiated Barclays Overweight $50
Mar-29-23Reiterated Oppenheimer Outperform $25 → $47
Mar-28-23Reiterated H.C. Wainwright Buy $37 → $44
Feb-24-23Initiated Citigroup Buy $20
Jun-02-22Resumed H.C. Wainwright Buy $16
Jan-12-22Initiated H.C. Wainwright Buy $13
Dec-17-21Initiated Oppenheimer Outperform $22
Mar-07-24 02:52PM
Mar-06-24 03:04AM
Mar-01-24 04:16PM
Feb-19-24 03:18PM
Feb-18-24 03:41PM
04:19PM Loading…
Feb-08-24 04:19PM
Jan-09-24 11:02AM
Jan-08-24 09:00AM
Jan-02-24 04:05PM
Dec-12-23 09:27AM
Dec-11-23 09:25AM
Dec-09-23 05:30PM
Dec-08-23 09:00AM
Dec-07-23 09:15AM
Dec-05-23 08:30AM
08:30AM Loading…
Nov-27-23 08:30AM
Nov-16-23 08:30AM
Nov-08-23 04:05PM
Nov-02-23 09:05AM
Nov-01-23 05:58AM
Oct-31-23 01:19AM
Oct-30-23 04:01PM
Oct-18-23 10:13AM
Oct-17-23 08:30AM
Oct-05-23 09:40AM
08:30AM
Sep-28-23 08:30AM
Aug-31-23 08:30AM
Aug-23-23 12:26PM
Jul-31-23 04:01PM
09:00AM Loading…
Jul-24-23 09:00AM
Jul-13-23 10:08AM
Jun-26-23 10:54AM
Jun-23-23 09:54PM
Jun-20-23 04:30PM
Jun-05-23 06:44AM
May-18-23 06:39AM
May-14-23 09:43AM
May-11-23 08:39AM
May-02-23 04:01PM
May-01-23 08:30AM
Apr-27-23 07:02AM
Apr-23-23 09:28AM
Apr-19-23 02:42PM
08:30AM
Apr-13-23 04:30PM
09:00AM
Apr-07-23 07:44AM
Mar-30-23 02:35PM
Mar-29-23 11:15PM
12:01PM
11:24AM
06:30AM
Mar-28-23 04:02PM
08:00AM
Mar-23-23 08:00AM
Mar-21-23 09:40AM
Mar-20-23 08:50AM
Mar-02-23 08:30AM
Jan-20-23 11:30AM
Jan-18-23 11:27AM
Jan-17-23 08:00AM
Jan-09-23 08:00AM
Jan-04-23 09:00AM
Dec-14-22 04:30PM
05:44AM
Dec-12-22 08:00AM
Nov-14-22 08:12AM
Nov-11-22 08:30AM
Nov-07-22 04:27PM
Nov-03-22 09:19AM
Oct-31-22 08:00AM
Oct-27-22 08:00AM
Oct-14-22 09:00AM
Sep-22-22 09:30AM
Sep-20-22 07:30AM
Sep-19-22 12:01PM
Aug-26-22 01:13PM
08:30AM
Aug-01-22 04:05PM
Jul-06-22 02:41PM
Jul-01-22 08:30AM
Jun-22-22 08:30AM
Jun-06-22 01:10PM
Jun-04-22 11:00AM
Jun-02-22 06:00PM
Jun-01-22 08:30AM
May-26-22 06:30PM
May-20-22 01:30PM
May-19-22 08:00AM
May-16-22 07:30AM
May-09-22 04:30PM
Apr-27-22 04:00PM
Apr-12-22 10:48AM
Apr-11-22 12:21PM
Apr-08-22 01:00PM
Apr-06-22 05:00PM
Mar-15-22 08:30AM
Mar-14-22 08:30AM
Mar-08-22 06:15PM
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
A2A Pharmaceuticals, Inc.10% OwnerJun 01 '23Sale34.5650,0001,728,1653,500,000Jun 02 05:00 PM
A2A Pharmaceuticals, Inc.10% OwnerMay 31 '23Sale33.8175,0002,535,7503,550,000Jun 02 05:00 PM
A2A Pharmaceuticals, Inc.10% OwnerMay 12 '23Sale33.8425,000846,0003,625,000May 17 07:13 AM
A2A Pharmaceuticals, Inc.10% OwnerMay 09 '23Sale34.50150,0005,175,7203,650,000May 10 05:19 PM
A2A Pharmaceuticals, Inc.10% OwnerMay 08 '23Sale33.99100,0003,399,3103,800,000May 10 05:19 PM
A2A Pharmaceuticals, Inc.10% OwnerApr 20 '23Sale29.12200,0005,823,7603,900,000Apr 26 08:36 AM
Chen BihuaDirectorMar 30 '23Buy30.00400,00012,000,0003,570,872Apr 03 04:30 PM